nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—Mitomycin—urinary bladder cancer	0.155	0.291	CbGbCtD
Levomilnacipran—CYP3A4—Thiotepa—urinary bladder cancer	0.0703	0.132	CbGbCtD
Levomilnacipran—CYP2C8—Fluorouracil—urinary bladder cancer	0.0563	0.106	CbGbCtD
Levomilnacipran—CYP2C8—Etoposide—urinary bladder cancer	0.047	0.0883	CbGbCtD
Levomilnacipran—ABCB1—Gemcitabine—urinary bladder cancer	0.0445	0.0837	CbGbCtD
Levomilnacipran—ABCB1—Cisplatin—urinary bladder cancer	0.0324	0.0608	CbGbCtD
Levomilnacipran—ABCB1—Etoposide—urinary bladder cancer	0.0318	0.0597	CbGbCtD
Levomilnacipran—ABCB1—Doxorubicin—urinary bladder cancer	0.0217	0.0407	CbGbCtD
Levomilnacipran—ABCB1—Methotrexate—urinary bladder cancer	0.021	0.0395	CbGbCtD
Levomilnacipran—CYP2D6—Doxorubicin—urinary bladder cancer	0.0204	0.0384	CbGbCtD
Levomilnacipran—CYP3A4—Etoposide—urinary bladder cancer	0.019	0.0358	CbGbCtD
Levomilnacipran—CYP3A4—Doxorubicin—urinary bladder cancer	0.013	0.0244	CbGbCtD
Levomilnacipran—CYP2C19—urine—urinary bladder cancer	0.00455	0.156	CbGeAlD
Levomilnacipran—CYP2J2—prostate gland—urinary bladder cancer	0.00366	0.125	CbGeAlD
Levomilnacipran—CYP3A4—urine—urinary bladder cancer	0.00269	0.0923	CbGeAlD
Levomilnacipran—CYP2D6—urine—urinary bladder cancer	0.00265	0.0908	CbGeAlD
Levomilnacipran—CYP2J2—female reproductive system—urinary bladder cancer	0.002	0.0685	CbGeAlD
Levomilnacipran—CYP2J2—vagina—urinary bladder cancer	0.00181	0.0619	CbGeAlD
Levomilnacipran—SLC6A4—female reproductive system—urinary bladder cancer	0.00108	0.0369	CbGeAlD
Levomilnacipran—CYP2C8—renal system—urinary bladder cancer	0.000972	0.0333	CbGeAlD
Levomilnacipran—SLC6A2—female reproductive system—urinary bladder cancer	0.000947	0.0325	CbGeAlD
Levomilnacipran—CYP2C19—vagina—urinary bladder cancer	0.000806	0.0277	CbGeAlD
Levomilnacipran—CYP2C8—female reproductive system—urinary bladder cancer	0.000778	0.0267	CbGeAlD
Levomilnacipran—CYP2C8—vagina—urinary bladder cancer	0.000704	0.0241	CbGeAlD
Levomilnacipran—ABCB1—prostate gland—urinary bladder cancer	0.000684	0.0234	CbGeAlD
Levomilnacipran—CYP3A4—renal system—urinary bladder cancer	0.000658	0.0226	CbGeAlD
Levomilnacipran—CYP2D6—renal system—urinary bladder cancer	0.000648	0.0222	CbGeAlD
Levomilnacipran—ABCB1—seminal vesicle—urinary bladder cancer	0.000578	0.0198	CbGeAlD
Levomilnacipran—SLC6A2—lymph node—urinary bladder cancer	0.000554	0.019	CbGeAlD
Levomilnacipran—CYP3A4—female reproductive system—urinary bladder cancer	0.000527	0.0181	CbGeAlD
Levomilnacipran—CYP2D6—female reproductive system—urinary bladder cancer	0.000519	0.0178	CbGeAlD
Levomilnacipran—ABCB1—epithelium—urinary bladder cancer	0.000502	0.0172	CbGeAlD
Levomilnacipran—ABCB1—renal system—urinary bladder cancer	0.000466	0.016	CbGeAlD
Levomilnacipran—ABCB1—urethra—urinary bladder cancer	0.000458	0.0157	CbGeAlD
Levomilnacipran—ABCB1—female reproductive system—urinary bladder cancer	0.000373	0.0128	CbGeAlD
Levomilnacipran—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000357	0.00133	CcSEcCtD
Levomilnacipran—Hypotension—Etoposide—urinary bladder cancer	0.000354	0.00132	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000353	0.00131	CcSEcCtD
Levomilnacipran—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000351	0.0013	CcSEcCtD
Levomilnacipran—Dysuria—Epirubicin—urinary bladder cancer	0.000349	0.0013	CcSEcCtD
Levomilnacipran—Neutropenia—Epirubicin—urinary bladder cancer	0.000349	0.0013	CcSEcCtD
Levomilnacipran—Dizziness—Thiotepa—urinary bladder cancer	0.000349	0.0013	CcSEcCtD
Levomilnacipran—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000348	0.00129	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000347	0.00129	CcSEcCtD
Levomilnacipran—Urticaria—Fluorouracil—urinary bladder cancer	0.000347	0.00129	CcSEcCtD
Levomilnacipran—Pollakiuria—Epirubicin—urinary bladder cancer	0.000345	0.00128	CcSEcCtD
Levomilnacipran—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000345	0.00128	CcSEcCtD
Levomilnacipran—Paraesthesia—Etoposide—urinary bladder cancer	0.00034	0.00126	CcSEcCtD
Levomilnacipran—Haematuria—Methotrexate—urinary bladder cancer	0.00034	0.00126	CcSEcCtD
Levomilnacipran—Weight decreased—Epirubicin—urinary bladder cancer	0.000338	0.00126	CcSEcCtD
Levomilnacipran—Dyspnoea—Etoposide—urinary bladder cancer	0.000338	0.00125	CcSEcCtD
Levomilnacipran—ABCB1—vagina—urinary bladder cancer	0.000337	0.0116	CbGeAlD
Levomilnacipran—Somnolence—Etoposide—urinary bladder cancer	0.000337	0.00125	CcSEcCtD
Levomilnacipran—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000337	0.00125	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000337	0.00125	CcSEcCtD
Levomilnacipran—Vomiting—Thiotepa—urinary bladder cancer	0.000336	0.00125	CcSEcCtD
Levomilnacipran—Rash—Thiotepa—urinary bladder cancer	0.000333	0.00124	CcSEcCtD
Levomilnacipran—Dermatitis—Thiotepa—urinary bladder cancer	0.000332	0.00123	CcSEcCtD
Levomilnacipran—Headache—Thiotepa—urinary bladder cancer	0.000331	0.00123	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.00033	0.00123	CcSEcCtD
Levomilnacipran—Decreased appetite—Etoposide—urinary bladder cancer	0.00033	0.00122	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000327	0.00122	CcSEcCtD
Levomilnacipran—Body temperature increased—Cisplatin—urinary bladder cancer	0.000327	0.00121	CcSEcCtD
Levomilnacipran—Fatigue—Etoposide—urinary bladder cancer	0.000327	0.00121	CcSEcCtD
Levomilnacipran—Constipation—Etoposide—urinary bladder cancer	0.000324	0.0012	CcSEcCtD
Levomilnacipran—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000324	0.0012	CcSEcCtD
Levomilnacipran—Dysuria—Doxorubicin—urinary bladder cancer	0.000323	0.0012	CcSEcCtD
Levomilnacipran—Neutropenia—Doxorubicin—urinary bladder cancer	0.000323	0.0012	CcSEcCtD
Levomilnacipran—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000322	0.00119	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000321	0.00119	CcSEcCtD
Levomilnacipran—Hepatitis—Methotrexate—urinary bladder cancer	0.00032	0.00119	CcSEcCtD
Levomilnacipran—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000319	0.00119	CcSEcCtD
Levomilnacipran—Asthenia—Gemcitabine—urinary bladder cancer	0.000319	0.00118	CcSEcCtD
Levomilnacipran—Haematuria—Epirubicin—urinary bladder cancer	0.000318	0.00118	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000316	0.00117	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000315	0.00117	CcSEcCtD
Levomilnacipran—Pruritus—Gemcitabine—urinary bladder cancer	0.000314	0.00117	CcSEcCtD
Levomilnacipran—Nausea—Thiotepa—urinary bladder cancer	0.000314	0.00116	CcSEcCtD
Levomilnacipran—Urethral disorder—Methotrexate—urinary bladder cancer	0.000313	0.00116	CcSEcCtD
Levomilnacipran—Weight decreased—Doxorubicin—urinary bladder cancer	0.000313	0.00116	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00031	0.00115	CcSEcCtD
Levomilnacipran—Pruritus—Fluorouracil—urinary bladder cancer	0.000309	0.00115	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000306	0.00113	CcSEcCtD
Levomilnacipran—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000305	0.00113	CcSEcCtD
Levomilnacipran—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000304	0.00113	CcSEcCtD
Levomilnacipran—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000302	0.00112	CcSEcCtD
Levomilnacipran—Urticaria—Etoposide—urinary bladder cancer	0.000301	0.00112	CcSEcCtD
Levomilnacipran—Abdominal pain—Etoposide—urinary bladder cancer	0.0003	0.00111	CcSEcCtD
Levomilnacipran—Body temperature increased—Etoposide—urinary bladder cancer	0.0003	0.00111	CcSEcCtD
Levomilnacipran—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.0003	0.00111	CcSEcCtD
Levomilnacipran—Hepatitis—Epirubicin—urinary bladder cancer	0.000299	0.00111	CcSEcCtD
Levomilnacipran—Eye disorder—Methotrexate—urinary bladder cancer	0.000299	0.00111	CcSEcCtD
Levomilnacipran—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000299	0.00111	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000298	0.00111	CcSEcCtD
Levomilnacipran—Asthenia—Cisplatin—urinary bladder cancer	0.000297	0.0011	CcSEcCtD
Levomilnacipran—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000297	0.0011	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000295	0.0011	CcSEcCtD
Levomilnacipran—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000295	0.00109	CcSEcCtD
Levomilnacipran—Haematuria—Doxorubicin—urinary bladder cancer	0.000294	0.00109	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000294	0.00109	CcSEcCtD
Levomilnacipran—Urethral disorder—Epirubicin—urinary bladder cancer	0.000293	0.00109	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000292	0.00108	CcSEcCtD
Levomilnacipran—Angiopathy—Methotrexate—urinary bladder cancer	0.00029	0.00108	CcSEcCtD
Levomilnacipran—Dizziness—Fluorouracil—urinary bladder cancer	0.000289	0.00107	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000288	0.00107	CcSEcCtD
Levomilnacipran—Chills—Methotrexate—urinary bladder cancer	0.000287	0.00106	CcSEcCtD
Levomilnacipran—Diarrhoea—Cisplatin—urinary bladder cancer	0.000283	0.00105	CcSEcCtD
Levomilnacipran—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000283	0.00105	CcSEcCtD
Levomilnacipran—Vomiting—Gemcitabine—urinary bladder cancer	0.000282	0.00105	CcSEcCtD
Levomilnacipran—Mental disorder—Methotrexate—urinary bladder cancer	0.00028	0.00104	CcSEcCtD
Levomilnacipran—Rash—Gemcitabine—urinary bladder cancer	0.00028	0.00104	CcSEcCtD
Levomilnacipran—Dermatitis—Gemcitabine—urinary bladder cancer	0.00028	0.00104	CcSEcCtD
Levomilnacipran—Eye disorder—Epirubicin—urinary bladder cancer	0.00028	0.00104	CcSEcCtD
Levomilnacipran—Hypersensitivity—Etoposide—urinary bladder cancer	0.000279	0.00104	CcSEcCtD
Levomilnacipran—Malnutrition—Methotrexate—urinary bladder cancer	0.000278	0.00103	CcSEcCtD
Levomilnacipran—Headache—Gemcitabine—urinary bladder cancer	0.000278	0.00103	CcSEcCtD
Levomilnacipran—Flushing—Epirubicin—urinary bladder cancer	0.000278	0.00103	CcSEcCtD
Levomilnacipran—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000278	0.00103	CcSEcCtD
Levomilnacipran—Vomiting—Fluorouracil—urinary bladder cancer	0.000278	0.00103	CcSEcCtD
Levomilnacipran—Hepatitis—Doxorubicin—urinary bladder cancer	0.000277	0.00103	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000275	0.00102	CcSEcCtD
Levomilnacipran—Rash—Fluorouracil—urinary bladder cancer	0.000275	0.00102	CcSEcCtD
Levomilnacipran—Dermatitis—Fluorouracil—urinary bladder cancer	0.000275	0.00102	CcSEcCtD
Levomilnacipran—Headache—Fluorouracil—urinary bladder cancer	0.000273	0.00102	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000273	0.00101	CcSEcCtD
Levomilnacipran—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000273	0.00101	CcSEcCtD
Levomilnacipran—Dysgeusia—Methotrexate—urinary bladder cancer	0.000273	0.00101	CcSEcCtD
Levomilnacipran—Asthenia—Etoposide—urinary bladder cancer	0.000272	0.00101	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000272	0.00101	CcSEcCtD
Levomilnacipran—Angiopathy—Epirubicin—urinary bladder cancer	0.000271	0.00101	CcSEcCtD
Levomilnacipran—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000271	0.00101	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.00027	0.001	CcSEcCtD
Levomilnacipran—Chills—Epirubicin—urinary bladder cancer	0.000268	0.000997	CcSEcCtD
Levomilnacipran—Pruritus—Etoposide—urinary bladder cancer	0.000268	0.000996	CcSEcCtD
Levomilnacipran—Nausea—Gemcitabine—urinary bladder cancer	0.000264	0.000979	CcSEcCtD
Levomilnacipran—Vomiting—Cisplatin—urinary bladder cancer	0.000263	0.000977	CcSEcCtD
Levomilnacipran—Vision blurred—Methotrexate—urinary bladder cancer	0.000262	0.000974	CcSEcCtD
Levomilnacipran—Mental disorder—Epirubicin—urinary bladder cancer	0.000262	0.000973	CcSEcCtD
Levomilnacipran—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000262	0.000972	CcSEcCtD
Levomilnacipran—Rash—Cisplatin—urinary bladder cancer	0.000261	0.000969	CcSEcCtD
Levomilnacipran—Dermatitis—Cisplatin—urinary bladder cancer	0.000261	0.000968	CcSEcCtD
Levomilnacipran—Malnutrition—Epirubicin—urinary bladder cancer	0.00026	0.000967	CcSEcCtD
Levomilnacipran—Diarrhoea—Etoposide—urinary bladder cancer	0.000259	0.000963	CcSEcCtD
Levomilnacipran—Nausea—Fluorouracil—urinary bladder cancer	0.000259	0.000963	CcSEcCtD
Levomilnacipran—Eye disorder—Doxorubicin—urinary bladder cancer	0.000259	0.00096	CcSEcCtD
Levomilnacipran—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000257	0.000954	CcSEcCtD
Levomilnacipran—Flushing—Doxorubicin—urinary bladder cancer	0.000257	0.000954	CcSEcCtD
Levomilnacipran—Flatulence—Epirubicin—urinary bladder cancer	0.000257	0.000953	CcSEcCtD
Levomilnacipran—Tension—Epirubicin—urinary bladder cancer	0.000256	0.000949	CcSEcCtD
Levomilnacipran—Dysgeusia—Epirubicin—urinary bladder cancer	0.000255	0.000947	CcSEcCtD
Levomilnacipran—Angiopathy—Doxorubicin—urinary bladder cancer	0.000251	0.000932	CcSEcCtD
Levomilnacipran—Dizziness—Etoposide—urinary bladder cancer	0.000251	0.000931	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000249	0.000926	CcSEcCtD
Levomilnacipran—Leukopenia—Methotrexate—urinary bladder cancer	0.000249	0.000925	CcSEcCtD
Levomilnacipran—Chills—Doxorubicin—urinary bladder cancer	0.000248	0.000922	CcSEcCtD
Levomilnacipran—Nausea—Cisplatin—urinary bladder cancer	0.000246	0.000913	CcSEcCtD
Levomilnacipran—Vision blurred—Epirubicin—urinary bladder cancer	0.000245	0.000911	CcSEcCtD
Levomilnacipran—Mental disorder—Doxorubicin—urinary bladder cancer	0.000242	0.0009	CcSEcCtD
Levomilnacipran—Convulsion—Methotrexate—urinary bladder cancer	0.000241	0.000895	CcSEcCtD
Levomilnacipran—Vomiting—Etoposide—urinary bladder cancer	0.000241	0.000895	CcSEcCtD
Levomilnacipran—Malnutrition—Doxorubicin—urinary bladder cancer	0.000241	0.000895	CcSEcCtD
Levomilnacipran—Agitation—Epirubicin—urinary bladder cancer	0.000239	0.000888	CcSEcCtD
Levomilnacipran—Rash—Etoposide—urinary bladder cancer	0.000239	0.000888	CcSEcCtD
Levomilnacipran—Dermatitis—Etoposide—urinary bladder cancer	0.000239	0.000887	CcSEcCtD
Levomilnacipran—Headache—Etoposide—urinary bladder cancer	0.000238	0.000882	CcSEcCtD
Levomilnacipran—Flatulence—Doxorubicin—urinary bladder cancer	0.000237	0.000882	CcSEcCtD
Levomilnacipran—Chest pain—Methotrexate—urinary bladder cancer	0.000237	0.00088	CcSEcCtD
Levomilnacipran—Tension—Doxorubicin—urinary bladder cancer	0.000236	0.000878	CcSEcCtD
Levomilnacipran—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000236	0.000876	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000235	0.000873	CcSEcCtD
Levomilnacipran—Syncope—Epirubicin—urinary bladder cancer	0.000234	0.000867	CcSEcCtD
Levomilnacipran—Leukopenia—Epirubicin—urinary bladder cancer	0.000233	0.000865	CcSEcCtD
Levomilnacipran—Palpitations—Epirubicin—urinary bladder cancer	0.00023	0.000854	CcSEcCtD
Levomilnacipran—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000229	0.00085	CcSEcCtD
Levomilnacipran—Vision blurred—Doxorubicin—urinary bladder cancer	0.000227	0.000843	CcSEcCtD
Levomilnacipran—Convulsion—Epirubicin—urinary bladder cancer	0.000226	0.000838	CcSEcCtD
Levomilnacipran—Infection—Methotrexate—urinary bladder cancer	0.000226	0.000838	CcSEcCtD
Levomilnacipran—Nausea—Etoposide—urinary bladder cancer	0.000225	0.000836	CcSEcCtD
Levomilnacipran—Hypertension—Epirubicin—urinary bladder cancer	0.000225	0.000835	CcSEcCtD
Levomilnacipran—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000223	0.000827	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000222	0.000826	CcSEcCtD
Levomilnacipran—Chest pain—Epirubicin—urinary bladder cancer	0.000222	0.000823	CcSEcCtD
Levomilnacipran—Agitation—Doxorubicin—urinary bladder cancer	0.000221	0.000822	CcSEcCtD
Levomilnacipran—Anxiety—Epirubicin—urinary bladder cancer	0.000221	0.00082	CcSEcCtD
Levomilnacipran—Skin disorder—Methotrexate—urinary bladder cancer	0.000221	0.000819	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00022	0.000817	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.00022	0.000815	CcSEcCtD
Levomilnacipran—ABCB1—lymph node—urinary bladder cancer	0.000218	0.00749	CbGeAlD
Levomilnacipran—Dry mouth—Epirubicin—urinary bladder cancer	0.000217	0.000805	CcSEcCtD
Levomilnacipran—Anorexia—Methotrexate—urinary bladder cancer	0.000216	0.000804	CcSEcCtD
Levomilnacipran—Syncope—Doxorubicin—urinary bladder cancer	0.000216	0.000802	CcSEcCtD
Levomilnacipran—Leukopenia—Doxorubicin—urinary bladder cancer	0.000216	0.000801	CcSEcCtD
Levomilnacipran—Palpitations—Doxorubicin—urinary bladder cancer	0.000213	0.000791	CcSEcCtD
Levomilnacipran—Hypotension—Methotrexate—urinary bladder cancer	0.000212	0.000788	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000212	0.00125	CbGpPWpGaD
Levomilnacipran—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000212	0.000786	CcSEcCtD
Levomilnacipran—Infection—Epirubicin—urinary bladder cancer	0.000211	0.000784	CcSEcCtD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000211	0.00125	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—CDK4—urinary bladder cancer	0.00021	0.00124	CbGpPWpGaD
Levomilnacipran—Shock—Epirubicin—urinary bladder cancer	0.000209	0.000776	CcSEcCtD
Levomilnacipran—Convulsion—Doxorubicin—urinary bladder cancer	0.000209	0.000775	CcSEcCtD
Levomilnacipran—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000208	0.000774	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000208	0.000773	CcSEcCtD
Levomilnacipran—Hypertension—Doxorubicin—urinary bladder cancer	0.000208	0.000772	CcSEcCtD
Levomilnacipran—Tachycardia—Epirubicin—urinary bladder cancer	0.000207	0.00077	CcSEcCtD
Levomilnacipran—Skin disorder—Epirubicin—urinary bladder cancer	0.000206	0.000766	CcSEcCtD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.000206	0.00122	CbGpPWpGaD
Levomilnacipran—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000206	0.00121	CbGpPWpGaD
Levomilnacipran—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000205	0.000763	CcSEcCtD
Levomilnacipran—Insomnia—Methotrexate—urinary bladder cancer	0.000205	0.000763	CcSEcCtD
Levomilnacipran—Chest pain—Doxorubicin—urinary bladder cancer	0.000205	0.000762	CcSEcCtD
Levomilnacipran—Anxiety—Doxorubicin—urinary bladder cancer	0.000204	0.000759	CcSEcCtD
Levomilnacipran—Paraesthesia—Methotrexate—urinary bladder cancer	0.000204	0.000757	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000204	0.000756	CcSEcCtD
Levomilnacipran—Anorexia—Epirubicin—urinary bladder cancer	0.000203	0.000752	CcSEcCtD
Levomilnacipran—Dyspnoea—Methotrexate—urinary bladder cancer	0.000202	0.000752	CcSEcCtD
Levomilnacipran—Somnolence—Methotrexate—urinary bladder cancer	0.000202	0.00075	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000201	0.00119	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TYMP—urinary bladder cancer	0.000201	0.00119	CbGpPWpGaD
Levomilnacipran—Dry mouth—Doxorubicin—urinary bladder cancer	0.000201	0.000745	CcSEcCtD
Levomilnacipran—Dyspepsia—Methotrexate—urinary bladder cancer	0.0002	0.000742	CcSEcCtD
Levomilnacipran—Hypotension—Epirubicin—urinary bladder cancer	0.000199	0.000737	CcSEcCtD
Levomilnacipran—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000198	0.00117	CbGpPWpGaD
Levomilnacipran—Decreased appetite—Methotrexate—urinary bladder cancer	0.000197	0.000733	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000196	0.000728	CcSEcCtD
Levomilnacipran—Fatigue—Methotrexate—urinary bladder cancer	0.000196	0.000727	CcSEcCtD
Levomilnacipran—Infection—Doxorubicin—urinary bladder cancer	0.000195	0.000725	CcSEcCtD
Levomilnacipran—Shock—Doxorubicin—urinary bladder cancer	0.000193	0.000718	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000193	0.00114	CbGpPWpGaD
Levomilnacipran—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000193	0.000716	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000193	0.000715	CcSEcCtD
Levomilnacipran—Insomnia—Epirubicin—urinary bladder cancer	0.000192	0.000714	CcSEcCtD
Levomilnacipran—Tachycardia—Doxorubicin—urinary bladder cancer	0.000192	0.000713	CcSEcCtD
Levomilnacipran—Skin disorder—Doxorubicin—urinary bladder cancer	0.000191	0.000709	CcSEcCtD
Levomilnacipran—Paraesthesia—Epirubicin—urinary bladder cancer	0.000191	0.000709	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000191	0.00113	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	0.000191	0.00113	CbGpPWpGaD
Levomilnacipran—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00019	0.000706	CcSEcCtD
Levomilnacipran—Dyspnoea—Epirubicin—urinary bladder cancer	0.000189	0.000703	CcSEcCtD
Levomilnacipran—CYP2C19—Biological oxidations—HPGDS—urinary bladder cancer	0.000189	0.00112	CbGpPWpGaD
Levomilnacipran—Somnolence—Epirubicin—urinary bladder cancer	0.000189	0.000701	CcSEcCtD
Levomilnacipran—Anorexia—Doxorubicin—urinary bladder cancer	0.000187	0.000696	CcSEcCtD
Levomilnacipran—Dyspepsia—Epirubicin—urinary bladder cancer	0.000187	0.000695	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000186	0.000689	CcSEcCtD
Levomilnacipran—Decreased appetite—Epirubicin—urinary bladder cancer	0.000185	0.000686	CcSEcCtD
Levomilnacipran—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000184	0.00109	CbGpPWpGaD
Levomilnacipran—Hypotension—Doxorubicin—urinary bladder cancer	0.000184	0.000682	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000183	0.000681	CcSEcCtD
Levomilnacipran—CYP2C19—Biological oxidations—GSTT1—urinary bladder cancer	0.000183	0.00108	CbGpPWpGaD
Levomilnacipran—Fatigue—Epirubicin—urinary bladder cancer	0.000183	0.00068	CcSEcCtD
Levomilnacipran—Constipation—Epirubicin—urinary bladder cancer	0.000182	0.000675	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—NAT2—urinary bladder cancer	0.000182	0.00107	CbGpPWpGaD
Levomilnacipran—Urticaria—Methotrexate—urinary bladder cancer	0.00018	0.00067	CcSEcCtD
Levomilnacipran—Body temperature increased—Methotrexate—urinary bladder cancer	0.00018	0.000667	CcSEcCtD
Levomilnacipran—Abdominal pain—Methotrexate—urinary bladder cancer	0.00018	0.000667	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000178	0.00105	CbGpPWpGaD
Levomilnacipran—Insomnia—Doxorubicin—urinary bladder cancer	0.000178	0.00066	CcSEcCtD
Levomilnacipran—CYP2C19—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000177	0.00105	CbGpPWpGaD
Levomilnacipran—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000177	0.000656	CcSEcCtD
Levomilnacipran—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000175	0.000651	CcSEcCtD
Levomilnacipran—Somnolence—Doxorubicin—urinary bladder cancer	0.000175	0.000649	CcSEcCtD
Levomilnacipran—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000174	0.00103	CbGpPWpGaD
Levomilnacipran—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000174	0.000645	CcSEcCtD
Levomilnacipran—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000173	0.000643	CcSEcCtD
Levomilnacipran—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000171	0.000635	CcSEcCtD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.00017	0.001	CbGpPWpGaD
Levomilnacipran—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00017	0.00063	CcSEcCtD
Levomilnacipran—Fatigue—Doxorubicin—urinary bladder cancer	0.00017	0.000629	CcSEcCtD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	0.000169	0.000998	CbGpPWpGaD
Levomilnacipran—Urticaria—Epirubicin—urinary bladder cancer	0.000169	0.000627	CcSEcCtD
Levomilnacipran—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000169	0.000996	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000169	0.000996	CbGpPWpGaD
Levomilnacipran—Constipation—Doxorubicin—urinary bladder cancer	0.000168	0.000624	CcSEcCtD
Levomilnacipran—Body temperature increased—Epirubicin—urinary bladder cancer	0.000168	0.000624	CcSEcCtD
Levomilnacipran—Abdominal pain—Epirubicin—urinary bladder cancer	0.000168	0.000624	CcSEcCtD
Levomilnacipran—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000167	0.000621	CcSEcCtD
Levomilnacipran—Asthenia—Methotrexate—urinary bladder cancer	0.000163	0.000605	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000161	0.000597	CcSEcCtD
Levomilnacipran—Pruritus—Methotrexate—urinary bladder cancer	0.000161	0.000597	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—RRM2—urinary bladder cancer	0.000157	0.000926	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000157	0.000581	CcSEcCtD
Levomilnacipran—Urticaria—Doxorubicin—urinary bladder cancer	0.000156	0.00058	CcSEcCtD
Levomilnacipran—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000155	0.000577	CcSEcCtD
Levomilnacipran—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000155	0.000577	CcSEcCtD
Levomilnacipran—Diarrhoea—Methotrexate—urinary bladder cancer	0.000155	0.000577	CcSEcCtD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000154	0.000909	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000153	0.000903	CbGpPWpGaD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000153	0.000902	CbGpPWpGaD
Levomilnacipran—Asthenia—Epirubicin—urinary bladder cancer	0.000152	0.000566	CcSEcCtD
Levomilnacipran—Pruritus—Epirubicin—urinary bladder cancer	0.00015	0.000558	CcSEcCtD
Levomilnacipran—Dizziness—Methotrexate—urinary bladder cancer	0.00015	0.000558	CcSEcCtD
Levomilnacipran—Diarrhoea—Epirubicin—urinary bladder cancer	0.000145	0.00054	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—HPGDS—urinary bladder cancer	0.000145	0.000857	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ENO2—urinary bladder cancer	0.000145	0.000857	CbGpPWpGaD
Levomilnacipran—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000145	0.000538	CcSEcCtD
Levomilnacipran—Vomiting—Methotrexate—urinary bladder cancer	0.000144	0.000536	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000144	0.000852	CbGpPWpGaD
Levomilnacipran—Rash—Methotrexate—urinary bladder cancer	0.000143	0.000532	CcSEcCtD
Levomilnacipran—Dermatitis—Methotrexate—urinary bladder cancer	0.000143	0.000531	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.000142	0.000841	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000142	0.00084	CbGpPWpGaD
Levomilnacipran—Headache—Methotrexate—urinary bladder cancer	0.000142	0.000528	CcSEcCtD
Levomilnacipran—Asthenia—Doxorubicin—urinary bladder cancer	0.000141	0.000524	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—GSTT1—urinary bladder cancer	0.000141	0.000831	CbGpPWpGaD
Levomilnacipran—Dizziness—Epirubicin—urinary bladder cancer	0.000141	0.000522	CcSEcCtD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000141	0.00083	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00014	0.000829	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000139	0.000822	CbGpPWpGaD
Levomilnacipran—Pruritus—Doxorubicin—urinary bladder cancer	0.000139	0.000517	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000139	0.000819	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000137	0.000806	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000136	0.000802	CbGpPWpGaD
Levomilnacipran—Vomiting—Epirubicin—urinary bladder cancer	0.000135	0.000502	CcSEcCtD
Levomilnacipran—Nausea—Methotrexate—urinary bladder cancer	0.000135	0.000501	CcSEcCtD
Levomilnacipran—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000135	0.0005	CcSEcCtD
Levomilnacipran—Rash—Epirubicin—urinary bladder cancer	0.000134	0.000498	CcSEcCtD
Levomilnacipran—Dermatitis—Epirubicin—urinary bladder cancer	0.000134	0.000497	CcSEcCtD
Levomilnacipran—Headache—Epirubicin—urinary bladder cancer	0.000133	0.000494	CcSEcCtD
Levomilnacipran—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000131	0.000773	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—PTEN—urinary bladder cancer	0.000131	0.000772	CbGpPWpGaD
Levomilnacipran—Dizziness—Doxorubicin—urinary bladder cancer	0.00013	0.000483	CcSEcCtD
Levomilnacipran—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000129	0.000762	CbGpPWpGaD
Levomilnacipran—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	0.000127	0.000751	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	0.000127	0.000751	CbGpPWpGaD
Levomilnacipran—Nausea—Epirubicin—urinary bladder cancer	0.000126	0.000469	CcSEcCtD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000125	0.000741	CbGpPWpGaD
Levomilnacipran—Vomiting—Doxorubicin—urinary bladder cancer	0.000125	0.000464	CcSEcCtD
Levomilnacipran—SLC6A4—Circadian rythm related genes—EP300—urinary bladder cancer	0.000125	0.000736	CbGpPWpGaD
Levomilnacipran—Rash—Doxorubicin—urinary bladder cancer	0.000124	0.00046	CcSEcCtD
Levomilnacipran—SLC6A4—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000124	0.000732	CbGpPWpGaD
Levomilnacipran—Dermatitis—Doxorubicin—urinary bladder cancer	0.000124	0.00046	CcSEcCtD
Levomilnacipran—Headache—Doxorubicin—urinary bladder cancer	0.000123	0.000457	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—NQO1—urinary bladder cancer	0.000117	0.000691	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000117	0.000691	CbGpPWpGaD
Levomilnacipran—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	0.000117	0.00069	CbGpPWpGaD
Levomilnacipran—Nausea—Doxorubicin—urinary bladder cancer	0.000117	0.000434	CcSEcCtD
Levomilnacipran—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	0.000116	0.000686	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000115	0.000681	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000115	0.000681	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	0.000115	0.000679	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000114	0.000672	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.000114	0.00067	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000111	0.000657	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	0.000111	0.000656	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.00011	0.000651	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000108	0.000638	CbGpPWpGaD
Levomilnacipran—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000107	0.000635	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000106	0.000627	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000106	0.000626	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	9.9e-05	0.000585	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTP1—urinary bladder cancer	9.76e-05	0.000576	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.44e-05	0.000558	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	9.4e-05	0.000555	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—TYMS—urinary bladder cancer	9.07e-05	0.000536	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.07e-05	0.000536	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GSTM1—urinary bladder cancer	8.97e-05	0.00053	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—NCOR1—urinary bladder cancer	8.97e-05	0.00053	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—urinary bladder cancer	8.92e-05	0.000527	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	8.73e-05	0.000515	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—GPX1—urinary bladder cancer	8.59e-05	0.000507	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ERCC2—urinary bladder cancer	8.43e-05	0.000498	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	8.31e-05	0.000491	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	8.27e-05	0.000489	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	8.27e-05	0.000489	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NAT1—urinary bladder cancer	8.27e-05	0.000489	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	8.24e-05	0.000486	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	8.14e-05	0.00048	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	8.09e-05	0.000478	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—MTHFR—urinary bladder cancer	7.93e-05	0.000468	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	7.79e-05	0.00046	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	7.65e-05	0.000452	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	7.6e-05	0.000449	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	7.57e-05	0.000447	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.54e-05	0.000445	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NAT1—urinary bladder cancer	7.39e-05	0.000436	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	7.39e-05	0.000436	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.26e-05	0.000429	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	7.22e-05	0.000426	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTO2—urinary bladder cancer	7.21e-05	0.000426	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NAT1—urinary bladder cancer	7.21e-05	0.000426	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	7.17e-05	0.000423	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	7.13e-05	0.000421	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	7.03e-05	0.000415	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.93e-05	0.000409	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	6.81e-05	0.000402	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NAT1—urinary bladder cancer	6.79e-05	0.000401	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	6.79e-05	0.000401	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	6.75e-05	0.000399	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	6.59e-05	0.000389	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.51e-05	0.000384	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	6.43e-05	0.00038	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPARG—urinary bladder cancer	6.43e-05	0.00038	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	6.27e-05	0.00037	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	6.21e-05	0.000367	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—CREBBP—urinary bladder cancer	6.17e-05	0.000365	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.13e-05	0.000362	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	6.08e-05	0.000359	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	6.05e-05	0.000357	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.94e-05	0.00035	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.91e-05	0.000349	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	5.74e-05	0.000339	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	5.61e-05	0.000331	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.6e-05	0.00033	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	5.59e-05	0.00033	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PRSS3—urinary bladder cancer	5.46e-05	0.000323	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	5.34e-05	0.000315	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	5.28e-05	0.000312	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	5.17e-05	0.000305	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	5.16e-05	0.000304	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	5.15e-05	0.000304	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS2—urinary bladder cancer	5.06e-05	0.000299	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.03e-05	0.000297	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMP—urinary bladder cancer	5.01e-05	0.000296	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.92e-05	0.00029	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.81e-05	0.000284	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.78e-05	0.000282	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.68e-05	0.000277	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NAT2—urinary bladder cancer	4.53e-05	0.000268	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.49e-05	0.000265	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.47e-05	0.000264	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4.44e-05	0.000262	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4.44e-05	0.000262	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTEN—urinary bladder cancer	4.41e-05	0.00026	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMP—urinary bladder cancer	4.37e-05	0.000258	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.3e-05	0.000254	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	4.29e-05	0.000253	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—EP300—urinary bladder cancer	4.21e-05	0.000248	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	4.19e-05	0.000248	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.12e-05	0.000243	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	4.06e-05	0.00024	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NAT2—urinary bladder cancer	4.05e-05	0.000239	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.99e-05	0.000236	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.96e-05	0.000234	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.95e-05	0.000233	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—RRM2—urinary bladder cancer	3.91e-05	0.000231	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NAT2—urinary bladder cancer	3.72e-05	0.00022	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.66e-05	0.000216	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	3.62e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ENO2—urinary bladder cancer	3.62e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.6e-05	0.000213	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.52e-05	0.000208	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	3.52e-05	0.000208	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.49e-05	0.000206	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.46e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.45e-05	0.000204	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.41e-05	0.000201	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.37e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	3.24e-05	0.000191	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ENO2—urinary bladder cancer	3.24e-05	0.000191	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.22e-05	0.00019	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.21e-05	0.00019	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HPGDS—urinary bladder cancer	3.16e-05	0.000186	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ENO2—urinary bladder cancer	3.16e-05	0.000186	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	3.14e-05	0.000185	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.09e-05	0.000182	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTT1—urinary bladder cancer	3.06e-05	0.000181	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	2.98e-05	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ENO2—urinary bladder cancer	2.98e-05	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NQO1—urinary bladder cancer	2.92e-05	0.000172	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	2.89e-05	0.00017	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.87e-05	0.000169	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.83e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.69e-05	0.000159	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.61e-05	0.000154	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.55e-05	0.00015	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.53e-05	0.000149	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.47e-05	0.000146	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.44e-05	0.000144	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.43e-05	0.000144	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.4e-05	0.000142	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.36e-05	0.000139	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.27e-05	0.000134	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.24e-05	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.24e-05	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.21e-05	0.00013	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	2.17e-05	0.000128	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.14e-05	0.000127	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTP1—urinary bladder cancer	2.12e-05	0.000125	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.11e-05	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.1e-05	0.000124	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—RRM2—urinary bladder cancer	2.1e-05	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—TYMS—urinary bladder cancer	2.02e-05	0.000119	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2e-05	0.000118	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	2e-05	0.000118	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	2e-05	0.000118	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	1.98e-05	0.000117	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.97e-05	0.000117	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.95e-05	0.000115	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.95e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.95e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.95e-05	0.000115	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.91e-05	0.000113	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.89e-05	0.000111	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.88e-05	0.000111	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.87e-05	0.00011	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—TYMS—urinary bladder cancer	1.86e-05	0.00011	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	1.84e-05	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	1.84e-05	0.000109	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.83e-05	0.000108	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.77e-05	0.000104	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPX1—urinary bladder cancer	1.76e-05	0.000104	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	1.73e-05	0.000102	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.72e-05	0.000102	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.62e-05	9.59e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.6e-05	9.47e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.57e-05	9.26e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.54e-05	9.1e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.43e-05	8.46e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.4e-05	8.25e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.38e-05	8.12e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.34e-05	7.93e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.32e-05	7.78e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.31e-05	7.72e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.27e-05	7.47e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.26e-05	7.45e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.22e-05	7.18e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.2e-05	7.1e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.2e-05	7.1e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.15e-05	6.8e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.13e-05	6.67e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.13e-05	6.65e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.1e-05	6.5e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—urinary bladder cancer	1.1e-05	6.49e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.06e-05	6.27e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.05e-05	6.2e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.04e-05	6.12e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—urinary bladder cancer	9.83e-06	5.8e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—urinary bladder cancer	9.59e-06	5.66e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—EP300—urinary bladder cancer	9.37e-06	5.53e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—EP300—urinary bladder cancer	9.15e-06	5.4e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—urinary bladder cancer	9.04e-06	5.34e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—EP300—urinary bladder cancer	8.62e-06	5.09e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARG—urinary bladder cancer	8.61e-06	5.09e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	8.27e-06	4.89e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.78e-06	4e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.91e-06	3.49e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.64e-06	3.33e-05	CbGpPWpGaD
